BPH AuthorityUnderstand the options. Find the right capability.
Start with the diagnosis

The BPH evaluation that makes treatment comparisons meaningful

Symptoms, prostate size, middle-lobe anatomy, bladder emptying, and personal priorities all change which options belong on the table.

Evidence reviewed August 14, 2026Clinical review pending; evidence sources are shown

BPH is a histologic enlargement of the prostate. Lower urinary tract symptoms are the lived problem. They overlap, but they are not synonyms: a man can have a large prostate with little obstruction or severe symptoms caused partly by the bladder, urethra, sleep, fluid balance, neurologic disease, infection, or medication.

A high-quality evaluation does not need every test for every person. It does need enough information to explain the likely symptom mechanism and to avoid matching a procedure to the wrong problem.

1. Define the symptom pattern and the bother

Weak stream, hesitancy, straining, intermittency, incomplete emptying, frequency, urgency, leakage, and nocturia do not carry the same diagnostic meaning. A validated symptom score such as the IPSS makes severity and response measurable, but it does not prove obstruction.

A bladder diary is particularly valuable when nighttime urination is prominent. It can distinguish reduced bladder capacity from excessive nighttime urine production and reveal fluid or diuretic timing patterns.

2. Look for alternate diagnoses and complications

History should cover infection, blood in urine, stones, prior urethral instrumentation, pelvic radiation, neurologic disease, diabetes, constipation, sleep apnea, heart or kidney disease, and medications that affect urine production or bladder function.

Urinalysis is part of the primary evaluation. Renal function is checked when impairment is suspected, hydronephrosis or retention is present, or surgery is being considered. PSA is not a generic BPH requirement; it is used when cancer detection or treatment planning would change management.

3. Measure emptying and flow

Post-void residual can reveal incomplete emptying but cannot by itself distinguish obstruction from weak bladder contraction. One number is less informative than the clinical context and trend.

Uroflowmetry adds information about flow pattern and peak rate. A low flow suggests a problem but still cannot reliably separate prostate obstruction, urethral stricture, and detrusor weakness.

4. Define prostate size and shape before choosing a procedure

Imaging is central when procedural treatment is being considered. Prostate volume helps separate small-gland TUIP, moderate-gland office procedures or TURP, and large-gland enucleation, Aquablation, PAE, or simple prostatectomy pathways.

Shape matters. A middle lobe, intravesical protrusion, high bladder neck, long prostatic urethra, calcification, or asymmetric lateral lobes may change whether an implant, vapor treatment, incision, resection, or enucleation is technically appropriate.

5. Use cystoscopy and urodynamics selectively

Cystoscopy is useful when hematuria, stricture, prior surgery, bladder disease, or anatomy could change treatment. It is not required merely to assign an IPSS score.

Pressure-flow urodynamics is not routine for uncomplicated symptoms. It becomes valuable when the diagnosis is uncertain, bladder weakness is suspected, prior treatment failed, neurologic disease is present, or the consequences of operating on an unobstructed outlet would be high.

6. State the priorities before selecting the technology

  • How important is preserving antegrade ejaculation?
  • Is the priority lowest anesthesia burden, fastest recovery, strongest flow improvement, or lowest retreatment risk?
  • How acceptable are a catheter, temporary urinary irritation, a permanent implant, and an operating-room procedure?
  • Is tissue for pathology important?
  • Would the patient travel for a high-capability HoLEP, Aquablation, or PAE program?

Bottom line

Treatment selection becomes much clearer once the evaluation answers three questions: what is causing the symptoms, what anatomy must be treated, and which tradeoffs the patient actually values.

Useful next steps

Build a discussion mapCompare all treatmentsUnderstand provider capability
Evidence trail

Sources and evidence

Open the original guideline, regulatory record, or study. Evidence was last checked August 14, 2026.

  1. AUA Guideline (2026) Part I: Presentation and Evaluation The Journal of Urology · professional guideline · 2026
  2. Diagnostic Evaluation — Management of Non-neurogenic Male LUTS European Association of Urology · professional guideline · 2026
  3. Disease Management — Management of Non-neurogenic Male LUTS European Association of Urology · professional guideline · 2026